209 related articles for article (PubMed ID: 27358436)
1. Renal Function in Atrial Fibrillation: A Multifaceted Dilemma.
Hijazi Z; Wallentin L
Circulation; 2016 Jul; 134(1):48-51. PubMed ID: 27358436
[No Abstract] [Full Text] [Related]
2. Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.
McCarty D; Robinson A
Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):37-49. PubMed ID: 26378211
[TBL] [Abstract][Full Text] [Related]
3. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
4. Atrial fibrillation and chronic kidney disease: focus on rivaroxaban.
Barrios V; Górriz JL
J Comp Eff Res; 2015 Nov; 4(6):651-64. PubMed ID: 26388302
[TBL] [Abstract][Full Text] [Related]
5. Terminated.
Rosendaal FR; Reitsma PH
J Thromb Haemost; 2014 Jun; 12(6):813. PubMed ID: 24916285
[No Abstract] [Full Text] [Related]
6. Clinical trials and tribulations.
Greaves M
J Thromb Haemost; 2014 Jun; 12(6):822-3. PubMed ID: 24655890
[No Abstract] [Full Text] [Related]
7. [Anticoagulation for patients with non-valvular atrial fibrillation].
Mizoguchi T; Yasaka M
Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
[TBL] [Abstract][Full Text] [Related]
8. Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
Circulation; 2016 Jul; 134(2):e7-8. PubMed ID: 27400902
[No Abstract] [Full Text] [Related]
9. Letter by Imprialos et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
Imprialos K; Boutari C; Stavropoulos K
Circulation; 2016 Jul; 134(2):e5-6. PubMed ID: 27400901
[No Abstract] [Full Text] [Related]
10. Letter by Bouatou et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
Bouatou Y; El Biali M; Samer CF
Circulation; 2016 Jul; 134(2):e3-4. PubMed ID: 27400900
[No Abstract] [Full Text] [Related]
11. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
Saraf K; Morris PD; Garg P; Sheridan P; Storey R
Postgrad Med J; 2014 Sep; 90(1067):520-8. PubMed ID: 25085900
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
Martínez-Rubio A; Dan GA; Kaski JC
Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
14. PURLs: Direct oral anticoagulants or warfarin for A fib?
Lyon C; Reed A; Prasad S
J Fam Pract; 2017 Aug; 66(8):518-519. PubMed ID: 28783771
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
16. Warfarin pharmacogenetics in the era of new oral anticoagulants.
Wright GE
Clin Genet; 2015 Aug; 88(2):135-6. PubMed ID: 25970639
[No Abstract] [Full Text] [Related]
17. The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant naïve, new-onset nonvalvular atrial fibrillation.
Hurley C; Dai S; Sobieraj DM
Int J Cardiol; 2015 Aug; 192():1-2. PubMed ID: 25981569
[No Abstract] [Full Text] [Related]
18. Efficacy of direct factor Xa inhibitors compared to warfarin in preventing stroke in adults with non-valvular atrial fibrillation: a systematic review protocol.
Rasmussen KL; Hampton MD
JBI Database System Rev Implement Rep; 2016 Jun; 14(6):69-77. PubMed ID: 27532651
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in very elderly patients with atrial fibrillation: a single-center experience.
Weronska A; Broniatowska E; Papuga-Szela E; Undas A
Kardiol Pol; 2020 Feb; 78(2):154-157. PubMed ID: 32108756
[No Abstract] [Full Text] [Related]
20. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials.
Ntaios G; Papavasileiou V; Diener HC; Makaritsis K; Michel P
Int J Stroke; 2017 Aug; 12(6):589-596. PubMed ID: 28730948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
